doi:10.3969/j.issn.1673-8640.2015.03.024

Abstract

CLC Number:

R446.1

Figures/Tables 4

项目	HBsAg	HCV抗体	HIV抗体
$x -$	2.88	2.08	2.35
s	0.22	0.17	0.19
CV(%)	9.74	9.33	8.87

项目	HBsAg	HCV抗体	HIV抗体
$x -$	2.88	2.08	2.35
s	0.22	0.17	0.19
CV(%)	9.74	9.33	8.87

项目	一月	二月	三月	四月	五月	六月
$x -$	2.83	2.74	2.84	2.91	2.81	2.78
s	0.33	0.29	0.33	0.35	0.32	0.31
CV(%)	13.34	11.35	13.37	11.78	13.47	12.89

项目	一月	二月	三月	四月	五月	六月
$x -$	2.83	2.74	2.84	2.91	2.81	2.78
s	0.33	0.29	0.33	0.35	0.32	0.31
CV(%)	13.34	11.35	13.37	11.78	13.47	12.89

项目	一月	二月	三月	四月	五月	六月
$x -$	2.11	2.17	2.06	2.14	2.15	2.02
s	0.22	0.25	0.21	0.23	0.22	0.22
CV(%)	10.24	13.35	11.05	10.71	10.47	11.33

项目	一月	二月	三月	四月	五月	六月
$x -$	2.11	2.17	2.06	2.14	2.15	2.02
s	0.22	0.25	0.21	0.23	0.22	0.22
CV(%)	10.24	13.35	11.05	10.71	10.47	11.33

项目	一月	二月	三月	四月	五月	六月
$x -$	2.41	2.32	2.38	2.45	2.27	2.36
s	0.22	0.23	0.22	0.25	0.19	0.21
CV(%)	9.34	9.85	9.58	10.28	8.87	9.89

项目	一月	二月	三月	四月	五月	六月
$x -$	2.41	2.32	2.38	2.45	2.27	2.36
s	0.22	0.23	0.22	0.25	0.19	0.21
CV(%)	9.34	9.85	9.58	10.28	8.87	9.89

[1]	王治国. 临床检验质量控制技术[M]. 北京:人民卫生出版社, 2004:207-208.
[2]	孔祥沙, 季颖, 张海莹, 等. 甲型肝炎病毒抗体室内质控血清制备及评价[J]. 中华检验医学杂志, 2013,36(12):1146-1147.
[3]	韩光宇, 谭昆, 徐湛, 等. 自制抗-HIV临界值质控血清的室内质控及评价[J]. 国际检验医学杂志, 2013,34(6):711-712.
[4]	韦雪芳. ELISA检测HIV抗体室内质控血清的制备[J]. 检验医学与临床, 2011,8(20):2527-2528.
[5]	孙少岩, 吴敏慧. HCV抗体临界值质控血清的制备及应用[J]. 南京军医学院学报, 2001,23(3):181.

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 5

Related Articles 15

Recommended Articles

Metrics